USPTO serial 79340988
NRAVEL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 5, 2023
- Examiner
- ZARICK, DIANA G
- Law office
- TMO LAW OFFICE 126
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NRAVEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
R. Glenn Schroeder
R. Glenn Schroeder Schroeder Law PC110 Cooper Street #605Babylon, NY 11702UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations, in particular medicines for human beings and animals, for the treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; human and animal sample materials, for medical purposes, namely, tumor tissues and tissue grafts samples, blood, serum, plasma, urine, stools, allograft or xenograft tissue preparations, tissue cuts, blood plasma, blood serum, ascites being bodily fluids, cerebrospinal fluid, human and animal urine and human and animal stool; test kits of human and animal sample materials, comprising diagnostic reagents for medical purposes, namely, human and animal allograft and xenograft tissue, tissue cuts being biological tissue grafts and biological tissue cultures, blood plasma, blood serum, ascites being bodily fluids, cerebrospinal fluid, human and animal urine and human and animal stool; diagnostic preparations, in particular made by using molecular biological, molecular genetic, genetic engineering, immunological and biotechnical methods for medical use; therapeutic preparations, in particular made by using molecular biological, molecular genetic, genetic engineering, immunological and biotechnical methods, for medical use for the treatment of cancer; biological material collections, namely, biological tissue cultures for medical purposes; cancer material collections, namely, biological tissue being resected and biopsy tumor and adjacent non-tumor tissue from the human body including epithelial, connective, muscular, and nervous tissues, blood, serum, plasma, urine, stools for medical purposes; medical sample collections, namely, biological tissue cultures for medical purposes; biological sample collections from the human body, namely, epithelial, connective, muscular, and nervous tissues, blood, serum, plasma, urine, stools for medical purposes; biopsy material collections, namely, biological tissue in the nature of blood, biological tissue grafts and biological tissue cultures for medical purposes; all the afore-mentioned in particular with regard to the field of oncology | ACTIVE | — |
| 042 | Collection of clinical data for medical research and development of therapeutics and diagnostics; collecting genetic, medical, biomedical, biologic, chemical and biochemical data and information, in particular information generated through the use of imaging techniques, the use of liquid biopsy methods, the use of histopathological analysis and procedures, the use of genetic analysis and the use of genomics, proteomics, transcriptomics, metabolomics, lipidomics and/or glycomics studies and analysis for medical research; scientific and technological services, namely, research, design and development of new technology for others in the field of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; industrial analysis and research services in the field of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; design and development of computer hardware and software, in particular computer programs; scientific research for medical purposes, namely, molecular biological, immunological and histological laboratory services, in particular research and development in the field of human medical and veterinary medical diagnostics and therapy; typing of tissue and tissue samples, in particular using molecular biological, immunological, genetic engineering and histological methods for research purposes; preparation of human and animal biospecimen for research purposes; providing information and data relating to medical and veterinary research on human and animal biospecimen, in particular genomic, epigenomic, proteomic, phosphoproteomic, RNA, transcriptomic, lipidomic and metabolomic data; medical laboratory services for medical research purposes, other than for diagnostic or treatment purposes, namely, typing of tissue and tissue samples, in particular using molecular biological, immunological, genetic engineering and histological methods; database design and development; software as a service (SAAS) services, namely, hosting software for use by others for use as a database; installation, maintenance and updating of database software; providing scientific research information and results from an online searchable database; programming of computer software for databases; scientific and laboratory analysis using bioinformatics and computational biology in the field of oncology; all the afore-mentioned in particular with regard to the field of oncology | ACTIVE | — |
| 044 | Medical analyses in connection with the treatment of individuals including medical analysis of X-rays and blood samples, namely, medical testing for diagnostic and treatment purposes; medical clinic services; pharmaceutical advisory services; medical analysis services using bioinformatics and computational biology, for patient diagnostic and treatment purposes; providing supporting services and advice to hospitals and other medical care centres, namely, collecting and stabilizing of human and animal biospecimens, providing advice related thereto, and the collection of related clinical data for patient diagnostic and treatment purposes; all the afore-mentioned in particular with regard to the field of oncology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Indivumed GmbH
- Other trademarks owned by Indivumed GmbH
- Other trademarks owned by Indivumed GmbH
- Other trademarks owned by Indivumed GmbH
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NRAVEL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 22, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 14, 2024 | RINX | USPTO CORRECTION PROCESSED BY IB | — |
| Apr 23, 2024 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Apr 8, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 14, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 14, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 14, 2024 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Mar 13, 2024 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Mar 5, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 5, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 5, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 12, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 30, 2023 | RINX | USPTO CORRECTION PROCESSED BY IB | — |
| Oct 30, 2023 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Oct 25, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 25, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 24, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 19, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 19, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 30, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 30, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 30, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 11, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 11, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 11, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 11, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 11, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 25, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 24, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 24, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 28, 2023 | RFNP | REFUSAL PROCESSED BY IB | — |
| Jan 26, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 26, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 26, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 21, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 21, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 7, 2022 | CRSN | CORRECTION SENT TO IB | — |
| Dec 7, 2022 | CRSN | CORRECTION SENT TO IB | — |
| Dec 7, 2022 | CRCR | CORRECTION CREATED FOR IB | — |
| Dec 7, 2022 | CRCR | CORRECTION CREATED FOR IB | — |
| Jul 13, 2022 | RFNP | REFUSAL PROCESSED BY IB | — |
| Jun 23, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 22, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 28, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 25, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| May 23, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 19, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |